OGRMF - OrganiGram Holdings Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
7.98
+0.22 (+2.86%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close7.76
Open7.80
Bid0.00 x 0
Ask0.00 x 0
Day's Range7.65 - 8.14
52 Week Range2.97 - 8.14
Volume2,064,309
Avg. Volume911,888
Market Cap1.231B
Beta (3Y Monthly)2.92
PE Ratio (TTM)65.95
EPS (TTM)0.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Cannastocks2019 Investor Conference & Webinar Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...

  • CNW Group3 days ago

    Organigram Announces May 21st as Inaugural Date of Trading on the Nasdaq Global Select Market

    MONCTON , May 17, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that its common shares will commence trading on the Nasdaq Global Select Market under the symbol "OGI" on Tuesday May 21, 2019 . Organigram's common shares will continue to be listed and trade on the Toronto Venture Exchange (TSXV), also under the symbol "OGI".

  • CNW Group6 days ago

    Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th

    Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th

  • CNW Group7 days ago

    Organigram Strengthens Leadership Team with Government Relations Expert

    MONCTON, NB , May 13, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis is pleased to announce the recent appointment of government relations expert Cameron Bishop as the Company's Vice President, Public Affairs and Stakeholder Relations ( North America ).

  • Analyzing OrganiGram’s Valuation after Its Earnings
    Market Realist11 days ago

    Analyzing OrganiGram’s Valuation after Its Earnings

    OrganiGram: Analysts' Ratings and Target Price(Continued from Prior Part)ValuationsLately, cannabis stocks have seen a lot of pessimism. Some of the stocks are trading in the “oversold” territory. OrganiGram (OGRMF) has delivered gains since

  • OrganiGram: Analysts’ Ratings and Target Price
    Market Realist11 days ago

    OrganiGram: Analysts’ Ratings and Target Price

    OrganiGram: Analysts' Ratings and Target PriceOrganiGram updateOn April 15, OrganiGram (OGRMF) reported its second-quarter earnings with sales of 34.9 million Canadian dollars—compared to 3.7 million Canadian dollars in the same quarter the

  • This Major Pot Stock Is Headed to the Nasdaq
    Motley Fool11 days ago

    This Major Pot Stock Is Headed to the Nasdaq

    The only major Atlantic-based cannabis grower should soon be listed on a reputable U.S. exchange.

  • PR Newswire13 days ago

    CannaStocks2019 Q1 Investor Conference to be held on Wednesday May 15th at OTC Markets Group

    NEW YORK , May 6, 2019 /PRNewswire/ --  CannaStocks2019 today announced that its Q1 Investor Conference will be held at the OTC Markets Group offices in New York on May 15 th . Participating companies ...

  • Cannabis Sector Extended Its Losses Last Week
    Market Realist14 days ago

    Cannabis Sector Extended Its Losses Last Week

    Cannabis Sector Extended Its Losses Last WeekCannabis sector weakenedIn the week ending May 3, the cannabis sector extended its weakness. Most of the stocks ended in the negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) lost

  • Midday Update: How Cannabis Stocks Are Holding Up on May 3
    Market Realist16 days ago

    Midday Update: How Cannabis Stocks Are Holding Up on May 3

    Midday Update: How Cannabis Stocks Are Holding Up on May 3Cannabis stocks riseThe cannabis sector was on the rise in the first half of the day on May 3 after some major cannabis stocks received rating changes from Jefferies in the early morning.

  • Unlike Most Cannabis Stocks, This One Actually Makes Money
    InvestorPlace19 days ago

    Unlike Most Cannabis Stocks, This One Actually Makes Money

    OrganiGram Holdings (OTCMKTS:OGRMF) is a Canadian company that grows and sells medical marijuana. Its products include various strains, oils, and even vaporizers. Despite being a pot stock, I like this company and am considering buying some shares. Because, unlike most marijuana stocks, OrganiGram actually makes money!Source: Shutterstock As you are well aware, there is a frenzy occurring in the legal cannabis markets. You can't turn on the news or surf the web without coming across numerous stories about the marijuana industry. But it is important to understand that most of the cannabis companies are losing money and have no real future prospects.Consider all of the companies that are trading for fractions of a penny. Most of these companies will eventually become unable to raise cash to run their businesses. They will be bankrupt.InvestorPlace - Stock Market News, Stock Advice & Trading TipsEven well-known companies like Tilray (NYSE:TLRY) and General Cannabis (OTCMKTS:CANN) are losing money. * 7 Stocks That Are Soaring This Earnings Season This type of phenomenon is not new. It has occurred many times throughout history when an innovative new industry is formed. For example, when cars were invented there were soon over 300 companies that produced them. Eventually, there were three. The same type of consolidation happened in the internet boom. Click to Enlarge OrganiGram's profit trend is headed in the right direction. In 2014, the company lost 52 cents per share and in 2015 it lost 2 cents per share. 2016 was a breakeven year and in 2017 the loss was 11 cents per share. Last year, Organigram became profitable and reported earnings of 17 cents per share.Analysts estimate that OrganiGram will earn even more than that this year. The average estimate is 24 cents and the average price target is $11.65.To learn more about OrganiGram and other things happening in the Cannabis markets please check out this week's Kronical: More From InvestorPlace * 7 A-Rated Stocks That Are Under $10 * 7 Stocks That Are Soaring This Earnings Season * 5 Biotech Stocks for a Long-Lived Portfolio * 10 Times Apple's Hardware Failed Consumers -- And Hurt Its Business Compare Brokers The post Unlike Most Cannabis Stocks, This One Actually Makes Money appeared first on InvestorPlace.

  • Another Canadian pot stock is headed for a U.S. exchange
    MarketWatch19 days ago

    Another Canadian pot stock is headed for a U.S. exchange

    Organigram Holdings Inc. sold the second-most amount of recreational cannabis in Canada, but its market capitalization trails rivals handily — at least until it lists on the Nasdaq and gets access to more institutional investors.

  • How Cronos Group’s Valuation Stacks up Against Peers’
    Market Realist20 days ago

    How Cronos Group’s Valuation Stacks up Against Peers’

    Valuation in the Cannabis Sector: An End-of-Month Update(Continued from Prior Part)Cronos GroupCronos Group’s (CRON) recent valuation has been significantly higher than its historical average and that of peers (MJ) Aurora Cannabis (ACB), Aphria

  • Cannabis stocks mixed with Aleafia falling after earnings, Canopy updates on NYC hemp plans
    MarketWatch20 days ago

    Cannabis stocks mixed with Aleafia falling after earnings, Canopy updates on NYC hemp plans

    Cannabis stocks were mixed on Monday, with Aleafia Health losing ground after reporting earnings for 2018 and Organigram gaining on the news it has applied for a listing on Nasdaq.

  • CNW Group20 days ago

    Organigram Receives Perimeter License Amendment for Phases 4A and 4B as well as Initial 13 Cultivation Rooms in Phase 4A

    MONCTON, NB , April 30, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis is pleased to announce that it has received an expanded cultivation license from Health Canada in line with its previously announced Phase 4A and 4B expansion plans for its Moncton Campus.

  • Canopy Growth Rises on New York Hemp Facility Update
    Market Realist21 days ago

    Canopy Growth Rises on New York Hemp Facility Update

    Canopy Growth Rises on New York Hemp Facility UpdateCanopy Growth risesCanopy Growth (WEED)(CGC) stock rose about 4% in the first half of April 29’s trading session after it provided an update on its hemp industrial park in New York. The company

  • CNW Group23 days ago

    Organigram Announces Application to List on NASDAQ

    MONCTON, NB , April 26, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has applied to list its common shares on the NASDAQ Global Select Market ("NASDAQ"). In advance of anticipated listing on the NASDAQ, Organigram will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company's common shares on the NASDAQ remains subject to the approval of the NASDAQ and the satisfaction of all applicable listing and regulatory requirements. The Company will continue to maintain the listing of its common shares on the TSX Venture Exchange under the symbol "OGI".

  • Cannabis Stocks HEXO and APHA Gain while Others Struggle
    Market Realist25 days ago

    Cannabis Stocks HEXO and APHA Gain while Others Struggle

    CTST, TLRY, CGC, and Other Cannabis Stocks on the Rise(Continued from Prior Part)HEXO and APHA gain Today, HEXO (HEXO) was moving higher with a daily gain of 1.3% around noon while Aphria (APHA) wasn’t far behind with a gain of about 1%. When we

  • Benzinga27 days ago

    National Brands, Blue Sky Startups Address Investors At Cannabis Capital Conference

    More than 40 international companies applied to address the assembled investors and industry experts at the Benzinga Cannabis Capital Conference, from major industry players to rapidly growing startups looking to scale in new markets. Targeting the side-effects and complications of pharmaceutical injury treatment, Copeland Biosciences produces CBD and THC topical formulations developed to provide targeted pain management and injury treatment. Founder and CEO Dr. Glenn Copeland said he experienced these side effects firsthand in his career as a sports medicine doctor.

  • Benzinga29 days ago

    OrganiGram's Engel Looks Forward To 'Cannabis 2.0'

    One of the biggest surprises in the months since legalization is the diversity of the consumer base, Engel said. Another surprise: the strong demand for CBD, which Engel said OrganiGram continues to work to satisfy. The cannabis industry's growth wasn't a smooth ride and has had several headwinds, including supply challenges, Engel said.

  • ACCESSWIRElast month

    Cannabis Bargains After Aphria's News Started Sell-Off-THC Therapeutics, Inc.

    HENDERSON, NV / ACCESSWIRE / April 18, 2019 / Cannabis stocks were a sea of red on Monday, weighed down by Aphria Inc. after it swung to a wide loss in the third quarter that outweighed a surge in revenue. ...

  • CGC, HEXO, CTST Moving Higher Today
    Market Realistlast month

    CGC, HEXO, CTST Moving Higher Today

    CGC, HEXO, CTST Moving Higher TodayCannabis sector gains Today, the Horizons Marijuana Life Sciences ETF (HMMJ) gained about 0.3% and the ETFMG Alternative Harvest ETF (MJ) gained about 0.3% in the first half of the trading session. However, the

  • Cannabis stocks rally after 3 surveys find Americans increasingly favor legalization
    MarketWatchlast month

    Cannabis stocks rally after 3 surveys find Americans increasingly favor legalization

    Cannabis stocks rose across the board on Tuesday, as three separate surveys found Americans are increasingly in favor of legalization, demonstrating a major shift in opinion over the last two decades.